Document is current
Any future updates will be listed below
-
Authors
Davis, Jessie R.
Banskota, Samagya
Levy, Jonathan M. https://orcid.org/0000-0002-8061-7953
Newby, Gregory A. https://orcid.org/0000-0001-7869-2615
Wang, Xiao
Anzalone, Andrew V.
Nelson, Andrew T.
Chen, Peter J. https://orcid.org/0000-0002-1094-7180
Hennes, Andrew D.
An, Meirui https://orcid.org/0000-0002-4006-8670
Roh, Heejin
Randolph, Peyton B. https://orcid.org/0000-0001-6385-364X
Musunuru, Kiran https://orcid.org/0000-0003-3298-0368
Liu, David R. https://orcid.org/0000-0002-9943-7557
-
Funding
Funding for this research was provided by:
National Heart and Lung Institute (R01HL148769)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U01AI142756)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118062)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
Howard Hughes Medical Institute (Liu)
Bill and Melinda Gates Foundation (Liu)
- License Information
-
More Information
Article History
Received: 6 November 2022
Accepted: 22 March 2023
First Online: 4 May 2023
Competing interests
: J.R.D., S.B., J.M.L., A.V.A., G.A.N. and D.R.L. have filed patent applications on systems for PE delivery. J.R.D., J.M.L., A.V.A. and P.J.C. are currently employees of Prime Medicine. S.B. is currently an employee of Nvelop Therapeutics. K.M. is a consultant and equity holder of Verve Therapeutics and Variant Bio and a consultant for LEXEO Therapeutics. D.R.L. is a consultant for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine and Nvelop Therapeutics, companies that use or deliver genome editing or epigenome engineering agents, and owns equity in these companies. The remaining authors declare no competing interests.
